DE69331105D1 - Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen - Google Patents

Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen

Info

Publication number
DE69331105D1
DE69331105D1 DE69331105T DE69331105T DE69331105D1 DE 69331105 D1 DE69331105 D1 DE 69331105D1 DE 69331105 T DE69331105 T DE 69331105T DE 69331105 T DE69331105 T DE 69331105T DE 69331105 D1 DE69331105 D1 DE 69331105D1
Authority
DE
Germany
Prior art keywords
thioureleyne
inflammatable
immuned
thiabendazol
auto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331105T
Other languages
English (en)
Other versions
DE69331105T2 (de
Inventor
Alan N Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69331105D1 publication Critical patent/DE69331105D1/de
Application granted granted Critical
Publication of DE69331105T2 publication Critical patent/DE69331105T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
DE69331105T 1992-11-30 1993-11-30 Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen Expired - Fee Related DE69331105T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/982,702 US5310742A (en) 1992-11-30 1992-11-30 Uses for thioureylenes
PCT/US1993/011537 WO1994012183A1 (en) 1992-11-30 1993-11-30 Use of thioureleylenes and thiabendazole in autoimmune diseases

Publications (2)

Publication Number Publication Date
DE69331105D1 true DE69331105D1 (de) 2001-12-13
DE69331105T2 DE69331105T2 (de) 2002-07-11

Family

ID=25529427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331105T Expired - Fee Related DE69331105T2 (de) 1992-11-30 1993-11-30 Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen

Country Status (6)

Country Link
US (1) US5310742A (de)
EP (1) EP0670723B1 (de)
AU (1) AU5681694A (de)
DE (1) DE69331105T2 (de)
ES (1) ES2167356T3 (de)
WO (1) WO1994012183A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164641A1 (en) * 1993-06-07 1994-12-22 Dinah S. Singer Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
US6365616B1 (en) 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
ATE303159T1 (de) * 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20050003023A1 (en) * 2002-06-28 2005-01-06 Meisner Lorraine Faxon Topical composition for the treatment of psoriasis and related skin disorders
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US20050101534A1 (en) * 2002-11-13 2005-05-12 Sepracor, Inc. Compositions and methods for treating or preventing hearing impairment
US20090082451A1 (en) * 2004-09-01 2009-03-26 Trustees Of Boston University Use of thyroid hormone conversion inhibitors
EP2251010A1 (de) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Verwendungen von Thiabendazol und Derivaten davon zur Behandlung neurologischer Leiden
GB2527555B (en) * 2014-06-25 2018-09-19 Norbrook Lab Ltd Stable methimazole liquid compositions
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
WO2018132676A1 (en) * 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4609622A (en) * 1983-05-31 1986-09-02 Interthyr Research Foundation Inc. Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5
US4608341A (en) * 1983-05-31 1986-08-26 Interthyr Research Foundation, Inc. Living, fast-growing thyroid cell strain, FRTL-5
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4853227A (en) * 1987-10-23 1989-08-01 Ciba-Geigy Corporation Transdermal administration of a systemic active agent to a premature neonatal infant
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5010092A (en) * 1989-12-22 1991-04-23 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole
US5087441A (en) * 1989-12-22 1992-02-11 Wisconsin Alumni Research Foundation Protection against chemically-induced kidney damage by methimazole

Also Published As

Publication number Publication date
WO1994012183A1 (en) 1994-06-09
EP0670723A1 (de) 1995-09-13
EP0670723B1 (de) 2001-11-07
US5310742A (en) 1994-05-10
ES2167356T3 (es) 2002-05-16
AU5681694A (en) 1994-06-22
DE69331105T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
DE69322062D1 (de) Emulsionspolymere und ihre verwendung in haarfestigungszubereitungen
FI944549A (fi) Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
BR9406209A (pt) Derivados heterociclicos no tratamento de isquemia e doenças relacionadas
DE69331105T2 (de) Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen
DE69329087D1 (de) Bestimmung von Batterietemperatur und -typ
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69505657T2 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE68929361T2 (de) Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
DE69302257D1 (de) Pilzhemmendes und hautheilungsförderndes Mittel
DE69325451D1 (de) Verwendung von pyruvamid und ausgewählten pyruvyl-aminosäuren
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
DE4393944T1 (de) Verwendung von Ecdysteroiden in der Kosmetik und Dermatologie
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE69302234D1 (de) Menschliches Prohibitin und Prohibitin kodierende DNS
FI953423A (fi) Temotsolomidin tehostaminen ihmisten kasvainsoluissa
DE69230654D1 (de) Commiphora-Mukul-Extrakte und deren therapeutische Verwendung
DE69333264D1 (de) 3-Phenyl-5-pyridyl-Triazole und ihre Verwendung als Insektizide
FI941345A0 (fi) Retinoidit ja niiden käyttö ihosairauksien ja leukemian hoitoon
DE69822276D1 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
DE59306085D1 (de) Haar- und körperbehandlungsmittel
NO952194D0 (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
KR950005392U (ko) 인체의 안면과 뒷머리 방한 덮개
NO942686D0 (no) Anvendelse av 3-arylindol- og 3-arylindazolderivater ved behandling av psykoser
NO920961D0 (no) Hud- og saarpleiemiddel
NO920003D0 (no) Hud- og saarpleiemiddel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee